The collaboration is set to build a research and clinical infrastructure that will bolster big data medical research in the new Global Center for Pathogen Research & Human Health, in areas such as: genomics, single cell transcriptomics, population health, clinical applications, and chemical and drug discovery.
“Quantum will make the impossible possible, and when the Governor and I announced the Cleveland Innovation District earlier this year, this was the kind of innovative investment I hoped it would advance,” said Ohio Lt. Governor Jon Husted, Director of InnovateOhio.
“A partnership between these two great institutions will put Cleveland, and Ohio, on the map for advanced medical and scientific research, providing a unique opportunity to improve treatment options for patients and solve some of our greatest healthcare challenges.”
As part of the collaboration, IBM plans to install its first private sector, on-premises Quantum computing system (IBM Quantum System One) on Cleveland Clinic’s campus in Cleveland, U.S. In addition to an on-premises quantum system, Cleveland Clinic will also have access to IBM’s fleet of currently more than 20 quantum systems, accessible via the cloud.
The company also plans to install its first next-generation 1,000+ qubit quantum systems at its client facility, also to be located in Cleveland, by 2023.
“The COVID-19 pandemic has spawned one of the greatest races in the history of scientific discovery – one that demands unprecedented agility and speed,” said Arvind Krishna, Chairman and Chief Executive Officer of IBM.
“At the same time, science is experiencing a change of its own – with high performance computing, hybrid cloud, data, AI, and quantum computing, being used in new ways to break through long-standing bottlenecks in scientific discovery. Our new collaboration with Cleveland Clinic will combine their world-renowned expertise in healthcare and life sciences with IBM’s next-generation technologies to make scientific discovery faster, and the scope of that discovery larger than ever.”
According to the agreement, IBM will also provide access to a variety of research and commercial technologies, education and tools to assist Cleveland Clinic in accelerating discovery in healthcare and life science, including RoboRXN, a cloud-based platform that combines AI models and robots to help scientists design and synthesize new molecules remotely; the IBM Functional Genomics Platform, a cloud-based repository and research tool, which reveals the molecular features in viral and bacterial genomes, test development and treatment; Deep Search, which enables researchers access structured and unstructured data; and High-Performance Hybrid Cloud Computing technologies that can enable researchers to extend their workloads into the cloud.